Search
Fulcrum Therapeutics Inc
FULCAdd to Watchlist
3.725USD
-0.005-0.13%
Close 07-28 16:00（ET）Quotes delayed by 15 min
248.01MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-28The current earnings forecast score of Fulcrum Therapeutics Inc is 5.43, ranking 338 out of 385 in the Biotechnology & Medical Research industry. The average price target is 20.00, with a high of 25.00 and a low of 5.00.
Analyst Rating
Based on
7
analysts
Hold
Current Rating
6.833
Target Price
+83.69%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Fulcrum Therapeutics Inc
FULC
7
Beigene Ltd
ONC
28
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Fulcrum Therapeutics Inc's price target?
Analysts forecast that Fulcrum Therapeutics Inc's price target is USD 20.00, with the highest forecast at USD 25.00 and the lowest forecast at USD 5.00.
How have Fulcrum Therapeutics IncFULC's recent earnings per share performed?
The market expectation was USD -0.25, while Fulcrum Therapeutics IncFULC's earnings per share (EPS) for the previous quarter was USD -0.31. EPS for the next quarter is expected at USD -0.22.
What is the analyst rating for Fulcrum Therapeutics Inc?
Based on the ratings of Fulcrum Therapeutics Inc's stock from 7 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.